EVONIK INDUSTRIES AG

Evonik Industries AG unveils a 3‑year restructuring: workforce cuts, digitalisation, outsourcing and shuttering its unprofitable polyester unit to boost core profitability and global competitiveness.

German equity market steadied, DAX tops 25,000, but specialty‑chemistry stocks—Evonik, Lanxess—rise on strategic moves and analyst praise, offering clear growth paths amid global uncertainties.

Evonik’s 2029 restructuring adds 3,200 jobs, cuts a loss‑making polyester line, and boosts digitalisation to cut costs – a bold move to secure margins amid EU rules and global trade tensions.

Evonik’s breakthrough AEM membrane cuts green‑hydrogen costs 25%—but can it beat PEM tech, secure policy support, and survive RAG Foundation’s divestment to unlock true market upside?

Evonik’s €375 M convertible‑debt deal: low 1.45 % coupon, 27 % premium, boosting liquidity for R&D while keeping control – a strategic play amid regulatory tightening and tech shift.

Explore how Citigroup’s upbeat outlook and Goldman Sachs’s cautious stance shape Evonik Industries’ investment narrative, revealing the trade‑off between niche chemical strengths and market headwinds.

Evonik’s latest press conference highlights a strategic pivot toward high‑value specialty chemicals, boosted by sustainability initiatives and new R&D partnerships—an opportunity for investors to track its market‑expanding, eco‑friendly trajectory w…

MDAX’s latest gains reveal hidden opportunities and headwinds: from PUMA’s e‑commerce surge to Freenet’s high dividend, and regulatory impacts on Evonik and Lufthansa.

Mid‑cap German equity insights: Evonik’s specialty‑chemistry focus shows solid cash, AI‑supply‑chain gains, and green‑chemistry upside amid tightening EU rules.

Evonik Industries’ June 3 market‑watch update: a clear, logistics‑only notice for investors, outlining disclosure timing and its role in the German chemical market.